Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. Academic Article uri icon

Overview

abstract

  • PURPOSE: We performed a phase I study of 5-fluorouracil (5-FU), cisplatin and irinotecan. METHODS: Twenty-nine patients received cisplatin 25 mg/m(2) and bolus 5-FU 425 mg/m(2), along with irinotecan at 40, 50, and 65 mg/m(2) weekly for 4 out of 6 weeks. RESULTS: The maximum tolerated dose (MTD) for untreated patients was irinotecan 65 mg/m(2) while the MTD for previously treated patients was irinotecan 40 mg/m(2). Neutropenia and diarrhea were the major dose-limiting toxicities. Antitumor activity was noted in gastric, esophageal and pancreatic cancers. CONCLUSION: Because of the toxicity profile, combinations with continuous infusion 5-FU or capecitabine should be explored.

publication date

  • May 1, 2009

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Digestive System Neoplasms

Identity

Scopus Document Identifier

  • 65249086351

Digital Object Identifier (DOI)

  • 10.1080/07357900802406327

PubMed ID

  • 19219674

Additional Document Info

volume

  • 27

issue

  • 4